Blog
Daily evidence-led peptide research, regulatory news, expert digest and explainers. Every claim sourced; no AI tells.
Page 23
TAAR1: the metabolic target after GLP-1
A 2026 review argues TAAR1 shares key mechanisms with GLP-1 agonists and may reach aspects of metabolic disease that semaglutide addresses only indirectly.
Tirzepatide vs semaglutide: JASSO subgroup
SURMOUNT-5 subgroup: tirzepatide cut body weight by 20.1% vs 12.9% for semaglutide in 383 adults meeting Japan obesity disease criteria.
Why Dr. Reddy's paused generic semaglutide
Dr. Reddy's paused generic semaglutide after flagging an API quality issue. Here is what that means for patients, prescribers, and the generic GLP-1 market.
GLP-1 drugs, menstrual changes: FAERS 2026
A July 2026 FAERS study found semaglutide carries broader menstrual signals than tirzepatide or liraglutide, but the data cannot establish causation.
How GLP-1 guides bone marrow stem cells
A July 2026 study shows GLP-1 steers bone marrow stem cells toward bone via HIF-2 and AKT, protecting bone in glucocorticoid-treated mice.
GLP-1 drugs and US military adherence
A Military Health System study of 10,649 service members found tirzepatide led on adherence and persistence. Male members discontinued more often than females.
GLP-1 drugs and older adults: key evidence
A 2026 review covers tirzepatide, semaglutide, and liraglutide in older patients with obesity and type 2 diabetes, and where evidence has gaps.
MASLD: semaglutide and resmetirom explained
Two drugs now carry FDA approval for MASH. Here is what the phase 3 trial data says about each and where the evidence gaps remain.
GLP-1 drugs: psychiatric safety in 2026
Tirzepatide and semaglutide show comparable psychiatric profiles. Semaglutide beats older GLP-1 agents on depression and anxiety.
GLP-1 and bone loss from glucocorticoids
A July 2026 Stem Cell Reports paper shows GLP-1 shifts bone marrow stem cells toward bone via HIF-2alpha and AKT signaling in steroid-induced osteoporosis.
GLP-1 Drugs and Menstrual Changes
A 2026 FAERS study found semaglutide and tirzepatide linked to menstrual adverse events in females aged 12-55, adding a new dimension to GLP-1 counseling.
GLP-1 persistence in the US military
A 10,649-patient Military Health System database study found tirzepatide had 81.9% one-year persistence vs 70.7% for semaglutide and 34.2% for liraglutide.